In April 2026, the MV Hondius set off from Patagonia. A few weeks later, this cruise raised concerns among health institutions in Europe, North America, Africa, Australia and New Zealand: Some passengers had developed severe hantavirus cardiopulmonary syndrome (HCPS), three of them died.1 The outbreak drew attention to the pathogen, which was previously mainly associated […]
A case of anti-IgLON5 disease presenting with unusual clinical features has expanded current understanding of this rare autoimmune disorder. The case was investigated in a collaborative study between Euroimmun and clinics in Lübeck and Hamburg (Germany) and published in the Journal of Neurology. What is anti-IgLON5 disease? Anti-IgLON5 disease is a rare and poorly understood
#bettertogether Last spring, IDS and Euroimmun launched the new random access instrument IDS i20. This new automation solution followed the random access instruments IDS-i10 and IDS-iSYS already established in the market. The device was developed based on IDS’ 50 years of expertise in laboratory automation – always focusing on maximum convenience for the users and reliability. For
A new case of Homer-3 autoimmunity has been described, expanding the still limited body of knowledge about this rare autoimmune cerebellar disorder. The case was reported in the Journal of Neuroimmunology. What’s known so far To date, only 15 cases of Homer-3 autoantibody-associated disease have been described in the literature. The clinical phenotype in these
Following the successful launch of our new design last summer, another change at Euroimmun and IDS takes place, which makes our affiliation to Revvity, Inc. more visible. As part of our strategic development, we are consolidating the technical systems of our three companies. This will enable us to provide an even better service thanks to
